PMID- 33093008
OWN - NLM
STAT- MEDLINE
DCOM- 20211215
LR  - 20211215
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Jan
TI  - Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in 
      Patients With MDS With Normal Metaphase Karyotype.
PG  - e52-e56
LID - S2152-2650(20)30427-4 [pii]
LID - 10.1016/j.clml.2020.08.012 [doi]
AB  - BACKGROUND: Cytogenetic profile is an essential parameter in myelodysplastic 
      syndromes (MDS) risk stratification by both International Prognostic Symptom 
      Score (IPSS) and Revised (R)-IPSS. Almost one-half of patients with MDS have 
      normal cytogenetics by metaphase karyotype. Here we report the yield of MDS 
      fluorescence in situ hybridization (FISH) panel detecting cytogenetic 
      abnormalities in these patients and its impact on risk stratification. PATIENTS 
      AND METHODS: Among patients with normal metaphase karyotype, we assessed those 
      patients who had cytogenetic abnormalities detected by an MDS FISH panel, which 
      included probes for del (5), del (7), del (20), trisomy 8, and del (17p). Risk 
      stratification was calculated by both IPSS and R-IPSS. RESULTS: Of 1600 patients 
      with MDS with normal metaphase karyotype, 53 (3%) patients had cytogenetic 
      abnormality detected by MDS FISH panel. Integrating the MDS FISH panel 
      cytogenetics (IPSS + FISH restaging) resulted in upstaging the score, where 53% 
      of low-risk IPSS were upstaged to intermediate (int)-1, 56% of int-1 were 
      upstaged to int-2, and 78% of int-2 were upstaged to high risk. Based on the 
      R-IPSS, 61% of very low-risk patients, all low-risk patients, 92% of 
      intermediate-risk patients, and 50% of high-risk patients with FISH abnormalities 
      were upstaged, respectively. CONCLUSION: The yield of MDS FISH panel detecting 
      cytogenetic abnormalities in patients with normal karyotype by G-banding is low 
      and may not warrant ordering the panel in all patients. Among the 3% of patients 
      with normal karyotype who had cytogenetic abnormality detected by FISH, the risk 
      score assignment by IPSS and R-IPSS was upstaged.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Schwabkey, Zaker I
AU  - Schwabkey ZI
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
FAU - Al Ali, Najla
AU  - Al Ali N
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
FAU - Chan, Onyee
AU  - Chan O
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
FAU - Sallman, David A
AU  - Sallman DA
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
FAU - Padron, Eric
AU  - Padron E
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
FAU - Kuykendall, Andrew T
AU  - Kuykendall AT
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
FAU - Talati, Chetasi
AU  - Talati C
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
FAU - Sweet, Kendra
AU  - Sweet K
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
FAU - Lancet, Jeffrey E
AU  - Lancet JE
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.
FAU - Komrokji, Rami S
AU  - Komrokji RS
AD  - Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL. 
      Electronic address: Rami.komrokji@moffitt.org.
LA  - eng
PT  - Journal Article
DEP - 20200818
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
SB  - IM
MH  - Cytogenetics/*methods
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Karyotyping/*methods
MH  - Male
MH  - Metaphase/*genetics
MH  - Myelodysplastic Syndromes/mortality/*therapy
MH  - Risk Assessment
MH  - Risk Factors
MH  - Survival Analysis
OTO - NOTNLM
OT  - FISH
OT  - IPSS
OT  - MDS
OT  - Prognosis
OT  - R-IPSS
EDAT- 2020/10/24 06:00
MHDA- 2021/12/16 06:00
CRDT- 2020/10/23 05:38
PHST- 2020/05/29 00:00 [received]
PHST- 2020/08/05 00:00 [revised]
PHST- 2020/08/10 00:00 [accepted]
PHST- 2020/10/24 06:00 [pubmed]
PHST- 2021/12/16 06:00 [medline]
PHST- 2020/10/23 05:38 [entrez]
AID - S2152-2650(20)30427-4 [pii]
AID - 10.1016/j.clml.2020.08.012 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2021 Jan;21(1):e52-e56. doi: 
      10.1016/j.clml.2020.08.012. Epub 2020 Aug 18.